Base de dados : MEDLINE
Pesquisa : D03.066.515.540 [Categoria DeCS]
Referências encontradas : 55 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 55 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20842518
[Au] Autor:Hamatani H; Hiromura K; Kobatake K; Yoshida H; Kobayashi S; Yoneda N; Kayakabe K; Matsumoto T; Kuroiwa T; Ueki K; Nojima Y
[Ad] Endereço:Dialysis and Rheumatology Center, Toho Hospital, 1155 Azami, Kasagake-machi, Midori, Gunma 379-2311, Japan. hamatani@gunma-u.ac.jp
[Ti] Título:Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
[So] Source:Clin Exp Nephrol;14(6):619-24, 2010 Dec.
[Is] ISSN:1437-7799
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:We report two patients, a daughter and a mother, with lipoprotein glomerulopathy (LPG) who were successfully treated with niceritrol. Both patients carried a mutation in the apolipoprotein E (apoE) gene known as ApoE Tokyo/Maebashi. The daughter was found to have proteinuria at the age of 4 years. Four years later, she was diagnosed as having LPG based on a renal biopsy. She was treated with several medications including pravastatin, ethyl icosapentate, enalapril, warfarin and cyclophosphamide, all of which failed to reduce her proteinuria. At the age of 17 years, she exhibited an increase in proteinuria and a decline in renal function, despite ongoing treatment with pravastatin and enalapril. After switching from pravastatin to niceritrol, a marked reduction in the proteinuria and an improvement in renal function were observed. Her mother was found to have proteinuria at the age of 57 years and was diagnosed as having LPG based on a renal biopsy. She was also treated with niceritrol, resulting in an improvement in her proteinuria and renal function. These cases suggest that niceritrol might be a useful therapeutic option for LPG.
[Mh] Termos MeSH primário: Síndrome Nefrótica/tratamento farmacológico
Niceritrol/uso terapêutico
Proteinúria/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Apolipoproteínas E/genética
Criança
Pré-Escolar
Feminino
Seres Humanos
Glomérulos Renais/patologia
Meia-Idade
Mutação
Síndrome Nefrótica/genética
Linhagem
Proteinúria/genética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Apolipoproteins E); F54EHJ34MV (Niceritrol)
[Em] Mês de entrada:1103
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100916
[St] Status:MEDLINE
[do] DOI:10.1007/s10157-010-0333-9


  2 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20079958
[Au] Autor:Bostom AG
[Ti] Título:Binder blinders-niacin of omission?
[So] Source:Am J Kidney Dis;55(4):628-30, 2010 Apr.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Ensaios Clínicos como Assunto/normas
Hiperfosfatemia/tratamento farmacológico
Niacina/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Doença Crônica
Seres Humanos
Hiperfosfatemia/etiologia
Nefropatias/complicações
Niceritrol/uso terapêutico
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
2679MF687A (Niacin); F54EHJ34MV (Niceritrol)
[Em] Mês de entrada:1004
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100119
[St] Status:MEDLINE
[do] DOI:10.1053/j.ajkd.2009.12.015


  3 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15250280
[Au] Autor:Fujioka T; Ueno T; Matsumoto T; Watanabe H
[Ad] Endereço:Second Department of Internal Medicine, Nihon University School of Medicine.
[Ti] Título:[Dyslipidemia in renal failure].
[So] Source:Nihon Rinsho;62 Suppl 6:118-23, 2004 Jun.
[Is] ISSN:0047-1852
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Hiperlipidemias/tratamento farmacológico
Hiperlipidemias/etiologia
Falência Renal Crônica/complicações
Diálise Renal/efeitos adversos
[Mh] Termos MeSH secundário: Arteriosclerose/etiologia
Transtornos Cerebrovasculares/etiologia
HDL-Colesterol/sangue
LDL-Colesterol/sangue
Clofibrato/uso terapêutico
Doença das Coronárias/etiologia
Ácido Eicosapentaenoico/uso terapêutico
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hipolipemiantes/uso terapêutico
Lipoproteínas VLDL/sangue
Niceritrol/uso terapêutico
Doenças Vasculares Periféricas/etiologia
Diálise Peritoneal Ambulatorial Contínua/efeitos adversos
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypolipidemic Agents); 0 (Lipoproteins, VLDL); 0 (Triglycerides); 0 (very low density lipoprotein triglyceride); AAN7QOV9EA (Eicosapentaenoic Acid); F54EHJ34MV (Niceritrol); HPN91K7FU3 (Clofibrate)
[Em] Mês de entrada:0409
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040715
[St] Status:MEDLINE


  4 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12714122
[Au] Autor:Owada A; Suda S; Hata T
[Ad] Endereço:Department of Internal Medicine, Musashino Red Cross Hospital, Tokyo, Japan. o-hiromi@fg7.so-net.ne.jp
[Ti] Título:Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.
[So] Source:Am J Med;114(5):347-53, 2003 Apr 01.
[Is] ISSN:0002-9343
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Lipoprotein (a) [Lp(a)] levels increase in patients with renal disease. We administered niceritrol, a nicotinic acid derivative, to patients with chronic renal disease and a high serum Lp(a) level, and studied its effects on lipid metabolism, proteinuria, and renal function. METHODS: Thirty-three patients with chronic renal disease whose serum Lp(a) levels were > or = 15 mg/dL were randomly (but not blindly) assigned to treatment with niceritrol (n = 16) or to an untreated control group (n = 17). Parameters of lipid metabolism, excretion of urinary protein, and renal function were examined for 12 months. RESULTS: Changes in urinary protein excretion, as well as Lp(a) levels, differed significantly between the two groups. The mean (+/- SD) change from baseline in excretion of urinary protein was 0.77 +/- 1.23 g/d in the control group compared with -1.41 +/- 2.26 g/d in the niceritrol group at 12 months (P =0.003). Mean Lp(a) levels increased by 3 +/- 10 mg/dL in the control group compared with a decrease of 10 +/- 13 mg/dL in the niceritrol group at 12 months (P =0.004). The mean creatinine clearance declined by 10 +/- 12 mL/min in the control group, compared with 1 +/- 13 mL/min in the niceritrol group at 12 months (P =0.06). CONCLUSION: Lipid levels improved with niceritrol treatment, whereas the excretion of urinary protein decreased, perhaps slowing the rate of loss of renal function in chronic renal disease.
[Mh] Termos MeSH primário: Hiperlipidemias/complicações
Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/uso terapêutico
Nefropatias/complicações
Niceritrol/uso terapêutico
Proteinúria/prevenção & controle
[Mh] Termos MeSH secundário: Doença Crônica
Creatinina/metabolismo
Progressão da Doença
Feminino
Seres Humanos
Hiperlipidemias/sangue
Nefropatias/metabolismo
Masculino
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Hypolipidemic Agents); AYI8EX34EU (Creatinine); F54EHJ34MV (Niceritrol)
[Em] Mês de entrada:0305
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:030426
[St] Status:MEDLINE


  5 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12500244
[Au] Autor:Ieiri N; Hotta O; Taguma Y
[Ad] Endereço:Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan. no-ieiri@pf6.so-net.ne.jp
[Ti] Título:Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
[So] Source:Am J Kidney Dis;41(1):244-9, 2003 Jan.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lipoprotein glomerulopathy (LPG), characterized by glomerular lipoprotein thrombi, presumably composed of abnormal apolipoprotein E (apoE), leads to a progressive decline in renal function and eventually results in end-stage renal failure. A successful treatment for LPG has not yet been established. The authors treated a 36-year-old woman with LPG and exhibiting a nephrotic syndrome using an intensive lipid-lowering therapy consisting of fenofibrate (300 mg), niceritrol (750 mg), ethyl-icosapentate (1,800 mg), and probucol (500 mg). After the start of treatment, a remarkable decrease in urinary protein excretion and improvement in the hyperlipidemia were obtained; proteinuria was no longer detected 11 months after the initiation of treatment. A second biopsy performed 11 months after the initiation of treatment showed the complete disappearance of the lipoprotein thrombi that had been observed in a diffuse and global manner in the first renal biopsy. These findings suggest that typical LPG could be regressed if the abnormal lipoproteinemia is controlled sufficiently.
[Mh] Termos MeSH primário: Ácido Eicosapentaenoico/análogos & derivados
Hipolipemiantes/uso terapêutico
Nefropatias/diagnóstico
Nefropatias/tratamento farmacológico
Glomérulos Renais/efeitos dos fármacos
Glomérulos Renais/patologia
Lipídeos/sangue
Lipoproteínas/metabolismo
[Mh] Termos MeSH secundário: Adulto
Anticolesterolemiantes/uso terapêutico
Apolipoproteínas E/metabolismo
Combinação de Medicamentos
Ácido Eicosapentaenoico/uso terapêutico
Feminino
Fenofibrato/uso terapêutico
Seres Humanos
Glomérulos Renais/ultraestrutura
Masculino
Microscopia Eletrônica
Síndrome Nefrótica/diagnóstico
Síndrome Nefrótica/tratamento farmacológico
Síndrome Nefrótica/genética
Niceritrol/uso terapêutico
Linhagem
Probucol/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Apolipoproteins E); 0 (Drug Combinations); 0 (Hypolipidemic Agents); 0 (Lipids); 0 (Lipoproteins); 6GC8A4PAYH (eicosapentaenoic acid ethyl ester); AAN7QOV9EA (Eicosapentaenoic Acid); F54EHJ34MV (Niceritrol); P3CTH044XJ (Probucol); U202363UOS (Fenofibrate)
[Em] Mês de entrada:0301
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:021225
[St] Status:MEDLINE


  6 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12166344
[Au] Autor:Kinoshita M; Mikuni Y; Kudo M; Mori M; Horie E; Teramoto T; Matsushima T
[Ad] Endereço:Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan. makkino@med.teikyo-u.ac.jp
[Ti] Título:The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia.
[So] Source:J Int Med Res;30(3):271-81, 2002 May-Jun.
[Is] ISSN:0300-0605
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In the present study, we evaluated the effects of combination therapy with niceritrol and pravastatin in patients with hyperlipidaemia. A total of 62 patients with hyperlipidaemia, defined as total cholesterol levels above 220 mg/dl or triglyceride levels above 150 mg/dl, were recruited. Patients were divided into two groups: Group N received initial therapy with niceritrol 750-1500 mg/day, and those in Group P, pravastatin 10 mg/day. After 8 weeks, pravastatin 10 mg/day was added to the Group N treatment regimen for a further 8 weeks, while patients in Group P were given niceritrol 750-1500 mg/day in addition to pravastatin for 8 weeks. After the 8-week combination therapy study period, total cholesterol levels were 209.6 mg/dl in Group N and 220.7 mg/dl in Group P. Decreased triglyceride and lipoprotein(a) levels and increased high-density lipoprotein cholesterol levels, neither of which were achieved by pravastatin administration alone, were achieved with the combination of pravastatin and niceritrol. We conclude that when a single lipid-lowering drug fails to show therapeutic value, attempting combination therapy with a nicotinic acid preparation and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is worthwhile.
[Mh] Termos MeSH primário: Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/uso terapêutico
Niceritrol/uso terapêutico
Pravastatina/uso terapêutico
[Mh] Termos MeSH secundário: Colesterol/sangue
Colesterol/classificação
Quimioterapia Combinada
Feminino
Seres Humanos
Hipolipemiantes/administração & dosagem
Hipolipemiantes/efeitos adversos
Masculino
Meia-Idade
Niceritrol/administração & dosagem
Niceritrol/efeitos adversos
Pravastatina/administração & dosagem
Pravastatina/efeitos adversos
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol); F54EHJ34MV (Niceritrol); KXO2KT9N0G (Pravastatin)
[Em] Mês de entrada:0301
[Cu] Atualização por classe:170214
[Lr] Data última revisão:
170214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020809
[St] Status:MEDLINE


  7 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10971163
[Au] Autor:Wakasugi H; Futami T; Muso E; Ono T; Sasayama S; Inui K
[Ti] Título:Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient.
[So] Source:Nephron;86(1):97-8, 2000 Sep.
[Is] ISSN:1660-8151
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Mh] Termos MeSH primário: Anemia/induzido quimicamente
Hipolipemiantes/efeitos adversos
Niceritrol/efeitos adversos
Fosfatos/sangue
Diálise Renal/efeitos adversos
Trombocitopenia/induzido quimicamente
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Falência Renal Crônica/complicações
Falência Renal Crônica/terapia
Meia-Idade
Fatores de Tempo
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Phosphates); F54EHJ34MV (Niceritrol)
[Em] Mês de entrada:0010
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000906
[St] Status:MEDLINE


  8 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10441992
[Au] Autor:Saika Y; Kodama N; Kimura K; Fujii R; Ohtani H; Mune M; Mimura K; Maeda T; Yukawa S
[Ad] Endereço:Department of Internal Medicine, Ryoushukai Fujii Hospital, Osaka, Japan.
[Ti] Título:[Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
[So] Source:Nihon Jinzo Gakkai Shi;41(4):430-5, 1999 Jun.
[Is] ISSN:0385-2385
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Lp(a) has recently begun to attract attention as a risk factor of atherosclerotic disease, especially of ischemic heart disease. The Lp(a) concentration in the serum was shown to be important for chronic hemodialysis patients who have high mortality due to cardiovascular disease. Nicotinic acid derivatives, which are recognized for their capacity to lower the serum Lp(a) concentration, are effective against a high Lp(a) concentration in hemodialysis patients. In this study, niceritrol which is a nicotinic acid derivative was tested on hemodialysis patients and healthy controls by investigating the serum nicotinic acid level. Serum nicotinic acid concentration was also measured by the severity of renal dysfunction of patients untreated by niceritrol. The blood nicotinic acid concentration in healthy controls (n = 4) was changed after 2 hrs by the administration of niceritrol from 9.8 +/- 1.4 ng/ml to 192.7 +/- 23.1 ng/ml then slowly decreased. Chronic hemodialysis patients who take niceritrol every day showed the highest nicotinic acid serum concentration (500-1,000 ng/ml) on the day without hemodialysis and the serum level decreased with dialysis for 4 hrs to 25-80%. There was no significant difference in the nicotinic acid level in the serum between healthy controls (n = 10), chronic glomerulonephritis patients (n = 7), chronic renal failure patients (n = 8) and chronic hemodialysis patients (n = 17). Lp(a) concentration in the serum, however, was increased with greater severity of renal dysfunction, The side effect was not observed in any cases administered niceritrol. These data suggest nicotinate derivatives are effective for hemodialysis patients. High nicotinic acid level in the serum after treatment with niceritrol was lowered by dialysis. It is plausible that the nicotinate level in patients without niceritrol treatment did not influence the Lp(a) concentration, because there was no increase in the nicotinate level of the serum even if the patients had renal dysfunction.
[Mh] Termos MeSH primário: Hipolipemiantes/farmacocinética
Falência Renal Crônica/metabolismo
Niacina/sangue
Niceritrol/farmacocinética
Diálise Renal
[Mh] Termos MeSH secundário: Arteriosclerose/etiologia
Arteriosclerose/prevenção & controle
Seres Humanos
Hipolipemiantes/administração & dosagem
Falência Renal Crônica/terapia
Lipoproteína(a)/sangue
Niceritrol/administração & dosagem
Fatores de Risco
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Lipoprotein(a)); 2679MF687A (Niacin); F54EHJ34MV (Niceritrol)
[Em] Mês de entrada:9910
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990812
[St] Status:MEDLINE


  9 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10412757
[Au] Autor:Nishizawa Y; Shoji T; Tabata T; Inoue T; Morii H
[Ad] Endereço:Osaka City University Medical School, Japan. m6413203@med.osaka-cu.ac.jp
[Ti] Título:Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.
[So] Source:Kidney Int Suppl;71:S134-6, 1999 Jul.
[Is] ISSN:0098-6577
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with chronic renal failure often have alterations in lipoprotein profile including elevated very-low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL), and reduced high density lipoprotein (HDL) levels. Among these changes, raised IDL has been shown as an independent risk factor for atherosclerosis in hemodialysis patients. There are a limited number of studies reporting pharmacological approaches to IDL reduction in a uremic population. METHODS: We therefore summarize the effects of lipid-lowering drugs on IDL levels in patients with chronic renal failure treated by hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). RESULTS: First, a nicotinic acid analog niceritrol was given to hemodialysis patients. The drug increased HDL-cholesterol by 11%, but the reductions in VLDL-, IDL- and LDL-cholesterol were not significant. Second, CAPD patients were treated with a fibric acid derivative clinofibrate, which was excreted mainly into bile unlike other drugs in this class. The fibrate resulted in a remarkable reduction in VLDL-triglycerides, although it did not reduce IDL-cholesterol. Finally, an HMG-CoA reductase inhibitor (statin) pravastatin was used in HD and CAPD patients. Pravastatin reduced IDL- and LDL-cholesterol to the same extent (by 31%). None of these treatments caused serious adverse effects. CONCLUSIONS: We propose that IDL is an important target in the management of uremic dyslipidemia. To date, statins have been shown to be suitable for this purpose, although it remains to be clarified whether such an intervention reduces the risk for atherosclerotic vascular events in the uremic population.
[Mh] Termos MeSH primário: Hipolipemiantes/uso terapêutico
Lipoproteínas/efeitos dos fármacos
Uremia/sangue
[Mh] Termos MeSH secundário: LDL-Colesterol/sangue
LDL-Colesterol/efeitos dos fármacos
VLDL-Colesterol/sangue
VLDL-Colesterol/efeitos dos fármacos
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Lipoproteína(a)/sangue
Lipoproteína(a)/efeitos dos fármacos
Lipoproteínas/sangue
Lipoproteínas VLDL/sangue
Lipoproteínas VLDL/efeitos dos fármacos
Niceritrol/uso terapêutico
Diálise Peritoneal Ambulatorial Contínua
Fenoxiacetatos/uso terapêutico
Pravastatina/uso terapêutico
Diálise Renal
Uremia/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol, LDL); 0 (Cholesterol, VLDL); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypolipidemic Agents); 0 (Lipoprotein(a)); 0 (Lipoproteins); 0 (Lipoproteins, VLDL); 0 (Phenoxyacetates); 0374EZJ8CU (clinofibrate); F54EHJ34MV (Niceritrol); KXO2KT9N0G (Pravastatin)
[Em] Mês de entrada:9909
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990721
[St] Status:MEDLINE


  10 / 55 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:10193807
[Au] Autor:Kuboyama N; Watanabe Y; Yamaguchi M; Sato K; Suzuki T; Akiba T
[Ad] Endereço:Pharmaceutical Laboratory, Sanwa Kagaku Kenkyusho Co., Ltd, Mie, Japan.
[Ti] Título:Effects of niceritrol on faecal and urinary phosphate excretion in normal rats.
[So] Source:Nephrol Dial Transplant;14(3):610-4, 1999 Mar.
[Is] ISSN:0931-0509
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Phosphate binders such as aluminium hydroxide and calcium carbonate have several side-effects so that they are not ideal for clinical use. Recently we reported that administration of niceritrol at 750 mg/day to patients with HDL hypocholesterolaemia undergoing dialysis decreased the serum phosphate concentration. To clarify the mechanism of reduction of the serum phosphate concentration by niceritrol in patients undergoing dialysis, the effects of niceritrol on faecal and urinary phosphate excretion were examined in normal rats. METHODS: Niceritrol suspension in 5% gum arabic was administered for 4 days in normal rats. Faeces and urine were collected in metabolic cage and analysed for phosphate content. RESULTS AND CONCLUSIONS: Faecal phosphate excretion significantly increased in the groups with administration of 100 and 500 mg/kg niceritrol, but not in the group with 20 mg/kg. On the other hand, urinary phosphate excretion was not significantly changed in the groups on 20-500 mg/kg. Retention of phosphate was significantly suppressed in the groups on 100 and 500 mg/kg. A increased faecal phosphate excretion by niceritrol is presumably the mechanism by which serum phosphate concentration is reduced in dialysis patients.
[Mh] Termos MeSH primário: Fezes/química
Hipolipemiantes/farmacologia
Niceritrol/farmacologia
Fosfatos/metabolismo
[Mh] Termos MeSH secundário: Animais
Peso Corporal/efeitos dos fármacos
Cálcio/sangue
Ingestão de Alimentos/efeitos dos fármacos
Masculino
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Phosphates); F54EHJ34MV (Niceritrol); SY7Q814VUP (Calcium)
[Em] Mês de entrada:9905
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990408
[St] Status:MEDLINE



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde